ENDRA Life Sciences Files 8-K

TL;DR

ENDRA Life Sciences filed an 8-K on Nov 22, 2024, updating corporate info. No major news.

AI Summary

ENDRA Life Sciences Inc. filed an 8-K on November 22, 2024, reporting on other events and financial statements. The filing details the company's principal executive offices located at 3600 Green Court, Suite 350, Ann Arbor, MI 48105, and its telephone number is 734-335-0468. The company was formerly known as Endra Inc. before a name change on August 5, 2016.

Why It Matters

This 8-K filing provides updated corporate information and signals ongoing regulatory compliance for ENDRA Life Sciences Inc.

Risk Assessment

Risk Level: low — The filing is a routine corporate update and does not contain significant financial or operational news that would immediately impact the company's risk profile.

Key Players & Entities

• ENDRA Life Sciences Inc. (company) — Registrant
• November 22, 2024 (date) — Filing Date
• 3600 Green Court, Suite 350, Ann Arbor, MI 48105 (location) — Principal Executive Offices
• 734-335-0468 (phone_number) — Business Phone
• Endra Inc. (company) — Former Company Name
• August 5, 2016 (date) — Date of Name Change

FAQ

Key Financial Figures

• $0.0001 — ch registered Common stock, par value $0.0001 per share NDRA The Nasdaq Stock Mar

Filing Documents

• endra_8k.htm (8-K) — 25KB
• endra_ex991.htm (EX-99.1) — 8KB
• 0001654954-24-014793.txt ( ) — 158KB
• endra-20241122.xsd (EX-101.SCH) — 6KB
• endra-20241122_lab.xml (EX-101.LAB) — 14KB
• endra-20241122_cal.xml (EX-101.CAL) — 1KB
• endra-20241122_pre.xml (EX-101.PRE) — 9KB
• endra-20241122_def.xml (EX-101.DEF) — 2KB
• endra_8k_htm.xml (XML) — 4KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On November 21, 2024, ENDRA Life Sciences Inc. (the "Company") received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq"), informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). On November 22, 2024, the Company issued a press release announcing that it had regained compliance with the Nasdaq Minimum Bid Price Requirement, a copy of which is furnished as Exhibit 99.1 to this report. The information in this Item 7.01, including Exhibit 99.1 to this report, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to liability under that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the "Securities Act").

01 Other Information

Item 8.01 Other Information The information contained in the first paragraph of Item 7.01 of this Form 8-K is incorporated by reference into this Item 8.01.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated November 22, 2024, furnished herewith. 104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL). 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENDRA Life Sciences Inc. November 22, 2024 By: /s/ Richard Jacroux Name: Richard Jacroux Title: Chief Financial Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR